Patents Archives

News and Trends 27 Oct 2016

Boehringer enters the Biosimilar War against Blockbuster Humira

Boehringer Ingelheim just announced positive Phase III results for its Humira biosimilar. The company is joining many others in the fights to take a bite of the huge market that will be open for access when patents expire later this year. AbbVie’s Humira (adalimumab) is the best selling biological, with a jaw-dropping €13B ($14B) in […]

October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

carbios bioplastic bio recycling biodegradation

News and Trends 30 May 2016

French Biodegradable Plastics get 2 new key US Patents

Carbios has been granted two key US patents: One for a novel plastic-degrading microorganism, and another for the creation of plastics with a customised lifespan – which could help bioplastics break into more industrial applications. A Green Chemistry company from the French region of Auvergne, Carbios was founded in 2011 but already has had some major […]

May 30, 2016 - 3 minutesmins - By Denise Neves Gameiro

plant technologies greentech sundew biotech pat1

News and Trends 31 Mar 2016

From Anti-Ageing Creams to Alzheimer’s, this Biotech ‘Milks’ Tropical Plants

What if a biotech company would run its business with plants as raw materials? We looked at the biotech Plant Advanced Technologies (PAT) (France) aims to push back the frontiers of plant ‘sourcing’, by producing industrial biomolecules in plants without killing them! Only a few thousand of plants are quite well exploited in green biotech over around 450,000 […]

March 31, 2016 - 6 minutesmins - By Nicolas Sainte-Foie

News and Trends 29 Oct 2015

ERRATUM: Celyad’s US patent on TCR-deficient allogeneic CAR-T cells

ERRATUM: I published a first article on Celyad’s new patent on last Tuesday where I made an error of judgement. Celyad’s US patent covers allogeneic CAR-T modified to reduce immunogenicity. In my previous article, I wrote that Celyad stated having obtained the first US patent on CAR-T, which is wrong. Last Tuesday, Celyad announced having […]

October 29, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 25 Sep 2015

Roche’s patent halts an Amgen biosimilar debut

Amgen has had great success with its Avastin biosimilar, used as an inhibitor of angiogenesis in tumor growth. However, despite smashing the phase III trials, the Amgen-Allergan partnership still has to wait until 2022 for Roche’s European Avastin patent to expire. Amgen partnered up with Dublin based Allergan (Ireland) for a comprehensive oncology biosimilars pipeline […]

September 25, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 12 May 2015

US-based Juno Therapeutics purchased a German biotech

Juno Therapeutics has purchased Stage Cell Therapeutics, a privately held biotechnology company, based in Munich and Göttingen, Germany. The acquired technologies will support the development of the next generation CAR-T and TCR-T products, bringing Juno one step closer to beating cancer. The transaction further underlines Juno’s strategy of becoming a world leader in process development and in […]

May 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Apr 2015

Erytech Strengthens its Intellectual Property Position in the US

Erytech strengthed its intellectual property portfolio in the United States with the granting of a new patent and the further extension of the patent term of its core process patent. The French biopharmaceutical company develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs. The patent entitled “Medicament for […]

April 22, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Apr 2015

Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T

Just a week after announcing its intention to launch an IPO in the United States, Cardio3 Biosciences continues increasing its presence in the States. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a significant patent application broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen […]

April 8, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us